OBJECTIVE: Two series of experiments were designed to evaluate whether early arginine vasopressin improves acute outcome following resuscitation from traumatic brain injury and severe hemorrhagic hypotension. DESIGN: Prospective randomized, blinded animal study. SETTING: University laboratory. SUBJECTS: Thirty-three swine. INTERVENTIONS:In series 1 (n = 19), after traumatic brain injury with hemorrhage and 12 mins of shock (mean arterial pressure approximately 20 mmHg), survivors (n = 16) were initially resuscitated with 10 mL/kg crystalloid. After 30 mins, crystalloid and blood with either 0.1 unit x kg(-1) x hr(-1) arginine vasopressin or placebo was titrated to a mean arterial pressure target >or=60 mm Hg. After 90 mins, all received mannitol and the target was cerebral perfusion pressure >or=60 mm Hg. To test cerebrovascular function, 7.5% inhaled CO2 was administered periodically. In series 2 (n = 14), the identical protocol was followed except the shock period was 20 mins and survivors (n = 10) received a bolus of either arginine vasopressin (0.2 units/kg) or placebo during the initial fluid resuscitation. MEASUREMENTS AND MAIN RESULTS: In series 1, by 300 mins after traumatic brain injury with arginine vasopressin (n = 8) vs. placebo (n = 8), the fluid and transfusion requirements were reduced (both p < .01), intracranial pressure was improved (11 +/- 1 vs. 23 +/- 2 mmHg; p < .0001), and the CO2-evoked intracranial pressure elevation was reduced (7 +/- 2 vs. 26 +/- 3 mm Hg, p < .001), suggesting improved compliance. In series 2, with arginine vasopressin vs. placebo, cerebral perfusion pressure was more rapidly corrected (p < .05). With arginine vasopressin, five of five animals survived 300 mins, whereas three of five placebo animals died. The survival time with placebo was 54 +/- 4 mins (p < .05 vs. arginine vasopressin). CONCLUSIONS:Early supplemental arginine vasopressin rapidly corrected cerebral perfusion pressure, improved cerebrovascular compliance, and prevented circulatory collapse during fluid resuscitation of hemorrhagic shock after traumatic brain injury.
RCT Entities:
OBJECTIVE: Two series of experiments were designed to evaluate whether early arginine vasopressin improves acute outcome following resuscitation from traumatic brain injury and severe hemorrhagic hypotension. DESIGN: Prospective randomized, blinded animal study. SETTING: University laboratory. SUBJECTS: Thirty-three swine. INTERVENTIONS: In series 1 (n = 19), after traumatic brain injury with hemorrhage and 12 mins of shock (mean arterial pressure approximately 20 mm Hg), survivors (n = 16) were initially resuscitated with 10 mL/kg crystalloid. After 30 mins, crystalloid and blood with either 0.1 unit x kg(-1) x hr(-1) arginine vasopressin or placebo was titrated to a mean arterial pressure target >or=60 mm Hg. After 90 mins, all received mannitol and the target was cerebral perfusion pressure >or=60 mm Hg. To test cerebrovascular function, 7.5% inhaled CO2 was administered periodically. In series 2 (n = 14), the identical protocol was followed except the shock period was 20 mins and survivors (n = 10) received a bolus of either arginine vasopressin (0.2 units/kg) or placebo during the initial fluid resuscitation. MEASUREMENTS AND MAIN RESULTS: In series 1, by 300 mins after traumatic brain injury with arginine vasopressin (n = 8) vs. placebo (n = 8), the fluid and transfusion requirements were reduced (both p < .01), intracranial pressure was improved (11 +/- 1 vs. 23 +/- 2 mmHg; p < .0001), and the CO2-evoked intracranial pressure elevation was reduced (7 +/- 2 vs. 26 +/- 3 mm Hg, p < .001), suggesting improved compliance. In series 2, with arginine vasopressin vs. placebo, cerebral perfusion pressure was more rapidly corrected (p < .05). With arginine vasopressin, five of five animals survived 300 mins, whereas three of five placebo animals died. The survival time with placebo was 54 +/- 4 mins (p < .05 vs. arginine vasopressin). CONCLUSIONS: Early supplemental arginine vasopressin rapidly corrected cerebral perfusion pressure, improved cerebrovascular compliance, and prevented circulatory collapse during fluid resuscitation of hemorrhagic shock after traumatic brain injury.
Authors: Stephen M Cohn; Janet McCarthy; Ronald M Stewart; Rachelle B Jonas; Daniel L Dent; Joel E Michalek Journal: World J Surg Date: 2011-02 Impact factor: 3.352
Authors: Jan Küchler; Stephan Klaus; Ludger Bahlmann; Nils Onken; Alexander Keck; Emma Smith; Jan Gliemroth; Claudia Ditz Journal: Eur J Trauma Emerg Surg Date: 2019-05-24 Impact factor: 3.693
Authors: H G Lienhart; V Wenzel; J Braun; V Dörges; M Dünser; A Gries; W R Hasibeder; M Helm; R Lefering; T Schlechtriemen; H Trimmel; H Ulmer; W Ummenhofer; W G Voelckel; C Waydhas; K Lindner Journal: Anaesthesist Date: 2007-02 Impact factor: 1.041
Authors: Andrew R Mayer; Andrew B Dodd; Meghan S Vermillion; David D Stephenson; Irshad H Chaudry; Denis E Bragin; Andrew P Gigliotti; Rebecca J Dodd; Benjamin C Wasserott; Priyank Shukla; Rachel Kinsler; Sheila M Alonzo Journal: Neurosci Biobehav Rev Date: 2019-06-27 Impact factor: 8.989
Authors: Andrea Pasquale Cossu; Paolo Mura; Lorenzo Matteo De Giudici; Daniela Puddu; Laura Pasin; Maurizio Evangelista; Theodoros Xanthos; Mario Musu; Gabriele Finco Journal: Biomed Res Int Date: 2014-09-01 Impact factor: 3.411
Authors: François Beloncle; Ferhat Meziani; Nicolas Lerolle; Peter Radermacher; Pierre Asfar Journal: Ann Intensive Care Date: 2013-05-22 Impact factor: 6.925